Present Status, Challenges, and Prospects of Dihydromyricetin in the Battle against Cancer.
Present Status, Challenges, and Prospects of Dihydromyricetin in the Battle against Cancer.
复制标题
二氢杨梅素在抗癌领域的研究现状、挑战与前景
DOI：
10.3390/cancers14143487
复制
发表时间：
2022-07-18
期刊：
影响因子：
5.2
通讯作者：
Qin, Li
中科院分区：
文献类型：
--
作者：
Wu, Jiajun;Xiao, Zuowei;Li, Hongfang;Zhu, Neng;Gu, Jia;Wang, Wenmao;Liu, Chao;Wang, Wei;Qin, Li
随着诊断和治疗技术的进步，癌症患者的死亡率正在逐渐下降。然而，进一步遏制癌症的发展需要寻找创新和更有效的药物。天然草药在研发和医疗成本方面具有明显的优势，正受到越来越多的关注。二氢杨梅素是从显齿蛇葡萄茎叶中提取的一种具有良好抗癌活性的黄酮类化合物。本文综述了二氢杨梅素单独或与其他药物联用抗多种癌症的不同作用机制，为二氢杨梅素作为抗癌治疗药物的开发提供全面的参考。二氢杨梅素(DHM)是从显齿蛇葡萄中提取的一种天然黄酮类化合物，在传统中药中已有数百年的历史。DHM因其具有保护肝脏、保护心脏、抗氧化和抗炎等多种有益活性而备受关注。此外，DHM通过多种机制抑制肺癌、肝细胞癌、乳腺癌、黑色素瘤和恶性生殖系统的进展，包括抗血管生成、抗增殖、细胞凋亡和抑制侵袭和迁移。值得注意的是，DHM还在不同的水平上激活自噬，对癌症发挥双重调节作用。从机制上讲，DHM可以有效地调节哺乳动物雷帕霉素靶标、非编码核糖核酸介导的信号转导、磷脂酰肌醇3-激酶/蛋白激酶B通路、核因子-κB(NF-κB)、P53和内质网应激(ER Stress)驱动的不同类型癌症的信号转导。DHM还被证明对触发上皮-间充质转化(EMT)的各种调节因子具有抑制作用。此外，DHM与阿霉素、奈达铂等药物联合使用时，显示出显著的抗癌逆转能力。然而，DHM的低生物利用度限制了其潜在的应用，通过结构修饰和新剂型的探索来改善其应用前景。因此，在临床实践中，DHM可能成为单独或与传统抗癌策略联合治疗恶性肿瘤的有前途的候选药物。
With the advancements in diagnosis and treatment technology, the mortality of patients with cancer is gradually decreasing. However, further curbing cancer development requires searching for innovative and more effective drugs. Natural herbal medicine has apparent advantages in R&D and healthcare costs and is attracting increasing attention. Dihydromyricetin is a flavonoid compound with a promising anticancer effect extracted from the stems and leaves of Ampelopsis grossedentata. This paper reviews the different mechanisms of dihydromyricetin alone or in combination with other drugs against a variety of cancers to provide a comprehensive reference for the development of dihydromyricetin as an anticancer therapeutic agent. Dihydromyricetin (DHM) is a natural flavonoid compound extracted from Ampelopsis grossedentata that has been used for centuries in traditional Chinese medicine. DHM has attracted intensive attention due to its numerous beneficial activities, such as hepatoprotection, cardioprotection, antioxidant, and anti-inflammation. In addition, DHM inhibits the progression of cancers such as lung cancer, hepatocellular cancer, breast cancer, melanoma, and malignant reproductive systems through multiple mechanisms, including antiangiogenesis, antiproliferation, apoptosis, and inhibition of invasion and migration. Notably, DHM also activates autophagy at different levels, exerting a dual-regulatory effect on cancers. Mechanistically, DHM can effectively regulate mammalian target of rapamycin (mTOR), noncoding RNA-mediated signaling, phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) pathway, nuclear factor-κB (NF-κB), p53, and endoplasmic reticulum stress (ER stress)-driven signaling in different types of cancers. DHM has also been shown to have inhibitory effects on various regulators that trigger epithelial–mesenchymal transition (EMT). Furthermore, DHM exhibits a remarkable anticancer reversal ability when used in combination with drugs such as adriamycin, nedaplatin, and other drugs. However, the low bioavailability of DHM limits its potential applications, which are improved through structural modification and the exploration of novel dosage forms. Therefore, DHM may become a promising candidate for treating malignancies alone or combined with conventional anticancer strategies used in clinical practice.
登录
查看更多内容
影响因子：
4.7
作者：
通讯作者：
--
二氢杨梅素通过 ROS-STAT3 信号促进头颈鳞状细胞癌的自噬和凋亡
影响因子：
--
作者：
Fan TF;Wu TF;Bu LL;Ma SR;Li YC;Mao L;Sun ZJ;Zhang WF
通讯作者：
Zhang WF
影响因子：
--
作者：
Pavón MA;Arroyo-Solera I;Céspedes MV;Casanova I;León X;Mangues R
通讯作者：
Mangues R
影响因子：
4.5
作者：
Abuhelwa, Ahmad Y.;Foster, David J. R.;Upton, Richard N.
通讯作者：
Upton, Richard N.
影响因子：
4.3
作者：
Akil, Hussein;Perraud, Aurelie;Mathonnet, Muriel
通讯作者：
Mathonnet, Muriel